Sadik et al. identified that the activation of aryl hydrocarbon receptor (AHR) reduced anti-tumor immunity, and interleukin-4-induced-1 (IL4I1) was associated with AHR activity more than IDO-1 or TDO2 [86]. This evidence concerns the gene IDO1 and neoplasm.